Position of Johnson & Johnson (NYSE:JNJ) raised by Andesa Financial Management Inc.


Andesa Financial Management Inc. increased its stake in Johnson & Johnson (NYSE:JNJGet a rating) by 2.3% during the first quarter, according to its last disclosure to the SEC. The fund held 14,756 shares of the company after buying an additional 330 shares during the quarter. Johnson & Johnson accounts for about 1.4% of Andesa Financial Management Inc.’s investment portfolio, making the stock its 24th largest holding. Andesa Financial Management Inc.’s holdings in Johnson & Johnson were worth $2,615,000 at the end of the most recent period.

Other hedge funds have also recently increased or reduced their holdings in the company. Family CFO Inc acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $26,000. Professional Financial Advisors LLC increased its holdings of Johnson & Johnson stock by 47.9% in the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company valued at $37,000 after purchasing an additional 68 shares during the period. Joseph P. Lucia & Associates LLC acquired a new position in Johnson & Johnson stock during the first quarter worth $38,000. Advocacy Wealth Management Services LLC increased its holdings of Johnson & Johnson stock by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company valued at $41,000 after purchasing an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC acquired a new position in Johnson & Johnson stock during the fourth quarter worth $49,000. 68.78% of the shares are currently held by institutional investors.

Insider activity

In other news, EVP Kathryn E. Wengel sold 40,000 Johnson & Johnson shares in a trade dated Friday, June 10. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares of the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, accessible via this link. Separately, CAO Robert J. Decker sold 8,462 shares of the company in a trade that took place on Thursday, May 26. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares of the company, valued at approximately $2,785,140. The transaction was disclosed in a document filed with the SEC, accessible via the SEC website. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade that took place on Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares of the company, valued at $12,336,803. Disclosure of this sale can be found here. 0.35% of the shares are held by company insiders.

Johnson & Johnson trades down 1.1%

Shares of JNJ opened at $165.30 on Monday. The company’s 50-day moving average price is $174.25 and its 200-day moving average price is $174.73. The stock has a market capitalization of $434.60 billion, a P/E ratio of 24.06, a P/E/G ratio of 3.14 and a beta of 0.59. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet a rating) last reported quarterly earnings data on Tuesday, July 19. The company reported EPS of $2.59 for the quarter, beating analysts’ consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company posted revenue of $24.02 billion in the quarter, versus analyst estimates of $23.85 billion. During the same period last year, the company posted EPS of $2.48. The company’s quarterly revenue increased 3.0% from the same quarter last year. Analysts expect Johnson & Johnson to post earnings per share of 10.05 for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13 per share. The ex-dividend date is Monday, August 22. This represents an annualized dividend of $4.52 and a dividend yield of 2.73%. Johnson & Johnson’s dividend payout ratio is 65.79%.

A Wall Street analyst gives his opinion

A number of research analysts have recently published reports on the company. Morgan Stanley raised its price target on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a Friday, July 8 report. SVB Leerink lowered its target price on Johnson & Johnson from $200.00 to $194.00 in a Wednesday July 20 report. Citigroup lowered its price target on Johnson & Johnson from $205.00 to $201.00 in a Wednesday, July 20 report. Daiwa Capital Markets assumed cover for Johnson & Johnson in a Wednesday, June 22 report. They set an “outperformance” rating on the stock. Finally, UBS Group lowered its price target on Johnson & Johnson from $185.00 to $180.00 in a Thursday, July 21 report. Four research analysts gave the stock a hold rating, five issued a buy rating and one issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Company Profile

(Get a rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.

See also

Institutional ownership by quarter for Johnson & Johnson (NYSE: JNJ)



Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.